Antibodies against epidermal growth factor receptor (egfr) and uses thereof
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsRaghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
Life of this patent
Estimating the term…
Abstract
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
Claims30
A monoclonal antibody preparation comprising at least one monoclonal antibody which binds EGFR extracellular domain and comprises heavy and light chain variable region sequences comprising CDR1, CDR2, and CDR3 sequences, wherein the at least one monoclonal antibody is selected from the group consisting of:
- antibody (a) having heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 1, 2, and 3 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 4, 5, and 6, respectively;
- antibody (b) having heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 10, 11 and 12, respectively;
- and
- antibody (c) having heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 13, 14, and 15, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 16, 17, and 18, respectively.
A method of treating a subject with anti-EGFR antibodies, the method comprising administering to the subject:
- (a) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 1, 2, and 3 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 4, 5, and 6, respectively;
- (b) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 10, 11 and 12, respectively;
- and
- (c) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 13, 14, and 15 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
- 16, 17, and 18, respectively;
- wherein (a), (b) and (c) are administered to the subject at a molar ratio of 2:2:1 to each other.
Dependencies are inferred from the claim text.